Summary of Significant Accounting Policies (Details) - USD ($) |
3 Months Ended | 9 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|---|
Sep. 30, 2023 |
Sep. 30, 2022 |
Sep. 30, 2023 |
Sep. 30, 2022 |
Dec. 31, 2022 |
|
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| Foreign currency translation description | The functional currency of certain subsidiaries was the British Pound (“GBP”) (1.2386 and 1.2098 GBP to 1 US dollar, each as of September 30, 2023 and December 31, 2022, respectively) for balance sheet accounts, while expense accounts are translated at the weighted average exchange rate for the period (1.2655 and 1.1772 GBP to 1 US dollar for each of the three months ended September 30, 2023 and 2022, respectively, and 1.2442 and 1.2597 GBP to 1 US dollar each for the nine months ended September 30, 2023 and 2022, respectively). Equity accounts are translated at historical exchange rates. The resulting translation adjustments are recognized in stockholders’ (deficit) equity as a component of accumulated other comprehensive (loss) income. | ||||
| Comprehensive loss | $ 51,316 | $ (1,871,072) | $ 36,712 | $ (4,507,204) | |
| Foreign currency transaction gain (losses) | (2,952) | $ (1,485) | (14,031) | $ (14,151) | |
| Asset carrying amount | $ 12,405,084 | ||||
| Fair market value | (9,063,000) | ||||
| Assets impaired | 3,342,084 | ||||
| In-process research and development | 9,063,000 | ||||
| In-process research and development after impairment | 9,063,000 | ||||
| Loss on impairment | 9,063,000 | ||||
| In-process research and development assets | 2,300,000 | 2,300,000 | |||
| Minimum [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| Fair market value | 0 | ||||
| Assets exceeded market values | 1,462,084 | ||||
| In-process research and development | 0 | ||||
| Maximum [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| Fair market value | 9,063,000 | ||||
| Assets exceeded market values | 1,880,000 | ||||
| In-process research and development | 9,063,000 | ||||
| Revision of Prior Period, Accounting Standards Update, Adjustment [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| In-process research and development | 9,063,000 | 9,063,000 | |||
| In Process Research and Development [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| In-process research and development | $ 0 | $ 0 | |||
| CBR Pharma [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| Asset carrying amount | 1,462,084 | ||||
| 180 LP [Member] | |||||
| Summary of Significant Accounting Policies (Details) [Line Items] | |||||
| Asset carrying amount | $ 10,943,000 | ||||